NDATOPICALCREAM
Approved
Dec 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 15h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOTRIMIN ULTRA (butenafine hydrochloride) is a topical antifungal cream approved in 2001 for the treatment of fungal skin infections. It is a benzylamine antifungal that disrupts fungal cell membrane synthesis. Patients apply it directly to affected skin areas for conditions such as tinea pedis, tinea corporis, and tinea versicolor.
LOE Approaching
As LOE approaches, the brand team is likely transitioning from growth-focused roles to defensive strategy and cost-optimization, with reduced headcount expectations in commercial roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
Started Jan 2019
42 enrolled
Tinea Pedis
Career Relevance
LOTRIMIN ULTRA offers limited career growth potential as a mature, declining product with no linked job openings. Professionals on this brand should expect smaller team sizes, cost-focused mandates, and opportunities centered on competitive pricing, channel optimization, and defensive market share management rather than innovation or expansion.
Brand Manager
Worked on LOTRIMIN ULTRA at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.